Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bone Biologics Corp (OTC: BBLG).

Full DD Report for BBLG

You must become a subscriber to view this report.


Recent News from (OTC: BBLG)

Bone Biologics Completes $500,000 of Financing
Bone Biologics (OTCQB: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of $500,000 funding with Orthofix Holding, Inc. The funding represents the second round of a previously announced private placement. T...
Source: Business Wire
Date: March, 29 2018 08:00
Bone Biologics Release: New Preclinical Data For Spine Fusion Demonstrates Osteopromotive Properties
Data from this pilot animal study support rhNELL-1 advancing into later-stage preclinical testing by mid-2018 rhNELL-1 program remains on track to initiate human trials in 2019 Bone Biologics Corp. (OTC QB: BBLG), a developer of orthobiologic products for the spinal fusion, trau...
Source: Business Wire
Date: December, 20 2017 08:05
Bone Biologics Adds Osteoporosis and Trauma Indications to its Portfolio
Bone Biologics Corp (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, today has announced that it has expanded its Field of Use definition of the license agreement with the UCLA Technology Development Group on behalf of UC Regents for NEL...
Source: Business Wire
Date: August, 23 2017 13:33
Bone Biologics Completes $1.4 Million Round of Financing
Bone Biologics (OTC: BBLG), a developer of orthobiologic products for domestic and international spine fusion markets, announced today the completion of a $1.4 million funding round with Musculoskeletal Transplant Foundation and Hankey Capital, LLC. The funding represents the first round o...
Source: Business Wire
Date: August, 22 2017 17:54
Bone Biologics Announces Appointment of Bret Hankey to Company's Board of Directors
Bone Biologics Corp. (OTCQB: BBLG) announced that Bret Hankey has joined the company's board of directors. Mr. Hankey brings more than 15 years of operating and board director experience to the BBLG board. Since 2000, Mr. Hankey, age 40, has served in various capacities within the Hankey...
Source: Business Wire
Date: August, 03 2017 15:32
Bone Biologics Corporation Announces Commencement of a Private Placement of Securities
Bone Biologics Corporation (OTCQB: BBLG ) announced today that it has commenced a private offering of up to $10,000,000 of its securities. The securities will initially only be offered to persons who are either stockholders of the company or who are “accredited investors,” as ...
Source: Business Wire
Date: July, 24 2017 14:47
Bone Biologics Names Scott D. Boden, MD Chief Medical Advisor
Bone Biologics Corporation announced the engagement of Scott D. Boden, MD as Chief Medical Advisor. Dr. Boden is a tenured Professor of Orthopaedic Surgery at the Emory University School of Medicine and serves as the Director of the Emory Orthopaedics & Spine Center , Vice Chair of Or...
Source: Business Wire
Date: July, 06 2016 09:05
Bone Biologics Announces Signing of Option to License Revolutionary Bone Growth Factor Nell-1 from UCLA for Use in Osteoporosis
Exercise of the Option Would Expand Bone Biologics’ Exclusive Rights for Nell-1 Beyond Spinal Fusion Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the signing of an option agreement with UCLA, for an opportunity to ex...
Source: Business Wire
Date: June, 14 2016 09:00
Bone Biologics Completes $5.75 Million Round Of Financing
BOSTON , Feb. 29, 2016 /PRNewswire/ --  Bone Biologics (OTCQB: BBLG), an orthobiologic company focused on regenerative medicine, announced today the completion of a $5.75 million funding round with Musculoskeletal Transplant Foundation, OrthoFix Holdings, Inc. and Hankey Capital, ...
Source: PR Newswire
Date: February, 29 2016 10:15

 


About Bone Biologics Corp (OTC: BBLG)

Logo for Bone Biologics Corp (OTC: BBLG)

Bone Biologics was founded to pursue regenerative medicine for bone. Bone Biologics is currently focusing its development efforts of its bone graft substitute product on bone regeneration in spinal fusion. Our proprietary platform technology, NELL , is a recombinant human protein growth factor that is essential for normal bone development.

 

Contact Information

 

 

Current Management

  • Stephen LaNeve / CEO
  • Jeffrey Frelick / COO
  • Deina Walsh / CFO
  • Bruce Stroever / Chairman
  • John Booth /
  • Jimmy Deshland /
  • Bret Hankey /

Current Share Structure

  • Market Cap: $88,232,247 - 03/15/2018
  • Authorized: 100,000,000 - 03/15/2018
  • Issue and Outstanding: 43,679,330 - 03/15/2018

 


Recent Filings from (OTC: BBLG)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 03 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Amendment to a previously filed Form D
Filing Type: D/AFiling Source: edgar
Filing Date: March, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 29 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: December, 15 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 11 2017
Correspondence from the SEC to the Filer
Filing Type: UPLOADFiling Source: edgar
Filing Date: November, 16 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: October, 23 2017
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: October, 23 2017

 

 


Daily Technical Chart for (OTC: BBLG)

Daily Technical Chart for (OTC: BBLG)


Stay tuned for daily updates and more on (OTC: BBLG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BBLG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BBLG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BBLG and does not buy, sell, or trade any shares of BBLG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/